HC Wainwright Has Bullish Forecast for CRBU Q2 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at HC Wainwright raised their Q2 2026 EPS estimates for Caribou Biosciences in a research note issued to investors on Monday, May 11th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.29) per share for the quarter, up from their prior estimate of ($0.34). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.23) EPS.

CRBU has been the subject of a number of other reports. Truist Financial upgraded shares of Caribou Biosciences to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Caribou Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Caribou Biosciences Price Performance

CRBU stock opened at $2.03 on Wednesday. Caribou Biosciences has a 52-week low of $0.77 and a 52-week high of $3.54. The company has a 50-day moving average of $1.97 and a two-hundred day moving average of $1.86. The stock has a market capitalization of $201.34 million, a price-to-earnings ratio of -1.43 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The firm had revenue of $2.40 million during the quarter, compared to analysts’ expectations of $2.21 million. Caribou Biosciences had a negative net margin of 1,189.14% and a negative return on equity of 84.17%.

Institutional Trading of Caribou Biosciences

Several hedge funds have recently modified their holdings of CRBU. Westmount Partners LLC bought a new stake in shares of Caribou Biosciences during the first quarter valued at approximately $37,000. Invesco Ltd. grew its stake in shares of Caribou Biosciences by 187.2% during the fourth quarter. Invesco Ltd. now owns 35,063 shares of the company’s stock valued at $56,000 after purchasing an additional 22,856 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Caribou Biosciences during the fourth quarter valued at approximately $253,000. Man Group plc bought a new stake in shares of Caribou Biosciences during the fourth quarter valued at approximately $58,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Caribou Biosciences by 80.0% during the fourth quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock valued at $39,000 after purchasing an additional 10,824 shares during the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

Key Caribou Biosciences News

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Caribou Biosciences across multiple periods, including Q2 2026, Q3 2026, Q4 2026 and FY2026, and reiterated a Buy rating with an $11 price target. That kind of analyst support can help sentiment in CRBU shares. CRBU stock page
• Positive Sentiment: Caribou announced that two abstracts were accepted for oral presentations at the 2026 European Hematology Association meeting, covering its lead programs vispa-cel and CB-011. Oral presentations at a major medical conference can raise visibility for the pipeline and suggest ongoing scientific progress. EHA presentation announcement
• Neutral Sentiment: Brookline Capital Markets also updated several long-term earnings estimates for CRBU, with some near-term cuts and some longer-dated changes. These revisions matter for valuation, but the impact is mixed because the company is still expected to post losses for the foreseeable future.
• Negative Sentiment: Despite the analyst optimism, Caribou Biosciences is still projected to report negative EPS this year and next, underscoring continued losses and the likelihood that investors will focus on execution and funding needs rather than current profits.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.